erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

Prognostic Value of Serum Erythropoietin Levels in Acute Aortic Syndrome: A Real-world Analysis.

Gao Zhichun Z, Li Gaoshan G, Yin Chun C, Qian Dehui D et al.

It is currently unclear whether erythropoietin (EPO) has value in predicting the prognosis of acute aortic syndrome (AAS). A real-world analysis was conducted on the relationship between EPO and AAS outcomes. Primary endpoints were all-cause mortality and aortic-related mortality. The major adverse cardiac and cerebral events (MACCE) included all-cause mortality, acute myocardial infarction, stroke, and secondary procedures. Serum EPO concentration was examined using the Quantikine Human EPO ELISA. 254 AAS patients were recruited, of whom 73 died. The median time of follow-up was 18.1 months. In Cox regression analysis, log EPO (HR: 2.491, p<0.001), Stanford Type A (HR: 3.003, p<0.001), and treatment with surgery/thoracic endovascular aortic repair (TEVAR) (HR: 0.283, p<0.001) were independent predictors for all-cause mortality. In Kaplan-Meier curves, patients with EPO ≤ 16 IU/ml had significantly higher survival and event-free rates. Nomograms indicated that log EPO had the greatest contribution to AAS prognosis. In subgroup analysis, log EPO was an important prognostic indicator for type A AAS patients and those treated without surgery/TEAVR. In correlation analyses, EPO was positively correlated with c-reactive protein, IL-4, IL-6, monocytes and negatively correlated with albumin. The maximum diameter of the ascending aorta was positively correlated with EPO in AAS and aortic dissection (AoD) patients. The false lumen diameter and false lumen area were positively correlated with EPO in AoD subjects. The serum EPO level is closely associated with the adverse outcomes of AAS and has good prognostic value.

Association between beta-blocker and statin use and mental health in patients following pulmonary embolism: a prospective cohort study.

Sabljo Daniel D, Fischer Simone S, Berghaus Thomas M TM, Linseisen Jakob J et al.

Beta-blockers and statins are important drugs for the prevention of several cardiovascular diseases and are often prescribed in pulmonary embolism (PE) patients suffering from cardiovascular comorbidities. The present observational cohort study aims to investigate the potential association between the use of both beta-blockers and statins and the symptoms of depression and anxiety after PE. This analysis is based on 538 patients with acute PE who were admitted to the University hospital Augsburg between the years 2017 and 2022 and participated in the 'Lungenembolie-Augsburg (LEA)' study. The participants were interviewed during their hospital stay and received postal questionnaires three months after discharge. Symptoms of depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS). Multivariable linear regression models were used to evaluate the association between both regular beta-blocker and statin use prior to PE and depression and anxiety (HADS-Scores) three months after PE, respectively. While prior use of beta-blockers was significantly associated with depressiveness (β = 0.87 [0.01-1.74], p = 0.046) and anxiety (β = 0.87 [CI: 0.05-1.69], p = 0.037), statins did not show a significant association with either depression or anxiety. This study demonstrates an association between beta-blocker use and mental well-being of PE patients, which physicians must be aware of in the treatment of these patients.

Applicability of Regression Models for the Analysis of Ordinal PANSS Data in Schizophrenia: A Cohort Study.

Gvozdetskii Anton A, Prokopovich Galina G, Dobrovolskaya Alla A, Kushnerev Ivan I et al.

There is ongoing debate about the appropriate measurement level for symptom severity scores derived from clinical rating scales. The use of statistically inappropriate analytical methods for such data may distort results and lead to misinterpretations. To study the applicability of linear, beta, beta-binomial, and ordinal regression models for assessing changes in schizophrenia symptoms over time using the PANSS. The study cohort comprised patients diagnosed with schizophrenia and schizoaffective disorder. Symptom severity was quantified using the Positive and Negative Syndrome Scale (PANSS). Observation period, sex, brexpiprazole prescription upon admission, brexpiprazole monotherapy, and dropout from the study prior to completion of follow-up were used as covariates. Bayesian mixed-effects regression models were fitted to the obtained dataset: Model 1 (normal distribution), Model 2 (ordered beta distribution), Model 3 (beta-binomial distribution), and Model 4 (ordinal regression). The applicability of the models was assessed using the fit index γ, the proportion of predicted values that corresponded with any possible schizophrenia symptom score on the PANSS. A model was considered consistent at a γ=1. Additionally, the 95% Highest Density Interval (HDI) was calculated for γ. The study enrolled 24 patients with schizophrenia (75% of whom were men) aged 20 to 45 years. The fit index γ was 0.00 (95% HDI 0.00-0.00) for Model 1; 0.17 (95% HDI 0.14-0.21) for Model 2; 1.00 (95% HDI 1.00-1.00) for Model 3; and 1.00 (95% HDI 1.00-1.00) for Model 4. Model 1 allows results that fall outside the range of the PANSS. Models 1 and 2 can produce fractional values. Statistical models designed to analyze continuous variables (linear and beta regression) are inapplicable for ordinal variables and, in particular, changes in schizophrenia symptoms over time on the PANSS. Beta-binomial and ordinal regression models are recommended for rating scores.

Translating evidence of beta-blocker effectiveness following myocardial infarction.

Raveendra Keerthenan K, Gale Chris P CP